The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Common risk factors for heart failure and cancer
Open accessAbstract
Cardiovascular (CV) disease and cancer are the leading causes of death.1,2 Over the last decades, it has been appreciated that both CV disease and cancer are more common in individuals in whom risk factors for disease development accumulate, and preventative measures have been extremely important in driving down the incidence of disease.3-6 In general, the field of epidemiology, risk reduction, and preventative trials is divided into health care professionals who have an interest in either CV disease or cancer. As a result, the medical literature and medical practice has largely focused on the one disease, or the other. However, human individuals do not behave according to this dogma. Emerging data clearly suggest that identical risk factors may lead to CV disease in the one individual, but may cause cancer in another, or even both diseases in the same individual. This overlap exists between risk factors that are historically classified as 'CV risk factors' as these factors do equally strong predict cancer development. Therefore, we propose that a holistic approach might better estimate actual risks for CV disease and cancer. In this review, we summarize current insights in common behavioural risk factors for heart failure, being the most progressed and lethal form of CV disease, and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“It is now generally accepted that there is an angiogenic switch that either tips towards a net absence of angiogenesis, or tips towards enhanced angiogenesis, where neovascularization is active and supports tumour growth.(111)”
BackgroundMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 1×
“nate potential (CHIP) is a common observation in ageing subjects and has established relation with cancer formation, especially haematological malignancies, although many clones never become malignant.(67) Of interest, recently it was shown that CHIP also appears to be important for development of CV disease in genera…”
BackgroundTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Inflammatory Mechanisms in Obesity
Gregor, M. F., & Hotamisligil, G. S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101322 · Cited by 3,754 · cited 1×
“to DNA damage and increase in the likelihood of malignant mutations and cancer incidence.(54) As discussed in previous paragraphs, hypercholesterolaemia is an im-”
BackgroundBody Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M., Gavin, A., Visser, O., & Bray, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.07.005 · Cited by 2,478
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Gordon, D., Copeland, T., D’Agostino, D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809944 · Cited by 1,615
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497 · cited 1×
“92).(84) The recent published ARRIVE trial,”
Shared Risk Factors in Cardiovascular Disease and Cancer
Koene, R. J., Prizment, A. E., Blaes, A., & Konety, S. H. (2016) · Circulation · doi:10.1161/circulationaha.115.020406 · Cited by 1,494
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Komajda, M. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00700-5 · Cited by 1,222
Association Between Smoking and Risk of Bladder Cancer Among Men and Women
Freedman, N. D. (2011) · JAMA · doi:10.1001/jama.2011.1142 · Cited by 1,141
Yang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
European Society of Cardiology: Cardiovascular Disease Statistics 2017
Timmis, A., Petersen, S. E., Belle, E. V., Townsend, N. P., Conrad, N., Kaplon-Cieslicka, A., Kazakiewicz, D., Kavousi, M., Cvijic, M., Ignatiuk, B., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehag345 · Cited by 945
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942 · cited 1×
“An ‘over-active’ immune system can cause auto-immune like diseases such as fulminant myocarditis with a mortality rate of nearly 50%.(124) Because immune”
BackgroundRidker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
ECM remodeling in hypertensive heart disease
Berk, B. C., Fujiwara, K., & Lehoux, S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31044 · Cited by 902
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31924-x · Cited by 883
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E., & Ioannidis, J. P. A. (2015) · BMJ · doi:10.1136/bmj.g7607 · Cited by 860
The Progression of Hypertensive Heart Disease
Drazner, M. H. (2011) · Circulation · doi:10.1161/circulationaha.108.845792 · Cited by 844
Wolin, K. Y., Carson, K., & Colditz, G. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0285 · Cited by 778 · cited 1×
“It is speculated that 20% of the incidence of cancer is related to obesity.(52) Overweight and obesity”
BackgroundGheorghiade, M., Follath, F., Ponikowski, P., Barsuk, J. H., Blair, J. E. A., Cleland, J. G., Dickstein, K., Drazner, M. H., Fonarow, G. C., Jaarsma, T., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq045 · Cited by 739
Sano, S., Oshima, K., Wang, Y., MacLauchlan, S., Katanasaka, Y., Sano, M., Zuriaga, M. A., Yoshiyama, M., Goukassian, D., Cooper, M. A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.037 · Cited by 699
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 1×
“In the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) trial, the presence of diabetes mellitus was associated with a two-fold increase of either death or the composite outcome of CV death or hospitalization for HF in patients that used insulin therapy, up to an 50% increased ri…”
MethodLedwidge, M., Gallagher, J., Conlon, C., Tallon, E., O’Connell, E., Dawkins, I., Watson, C., O’Hanlon, R., Bermingham, M., Patle, A., et al. (2013) · JAMA · doi:10.1001/jama.2013.7588 · Cited by 664
Said, M. A., Verweij, N., & van der Harst, P. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1717 · Cited by 641
Inflammatory mediators in chronic heart failure: an overview
Anker, S. D., & von Haehling, S. (2004) · Heart · doi:10.1136/hrt.2002.007005 · Cited by 627 · cited 1×
“Several studies have provided evidence that progression of either HF or cancer is linked to enhanced tissue inflammation.(96,97) Several players have been recognized, including (but not limited to) dysregulated T-cells,(98,99) a switch in the macrophage population from M1 to M2 macrophages,(100,101) and influx of vari…”
BackgroundImmuno-oncology: understanding the function and dysfunction of the immune system in cancer
Finn, O. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds256 · Cited by 594
LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors
Mani, A., Radhakrishnan, J., Wang, H., Mani, A., Mani, M.-A., Nelson-Williams, C., Carew, K. S., Mane, S., Najmabadi, H., Wu, D., et al. (2007) · Science · doi:10.1126/science.1136370 · Cited by 588
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0041 · Cited by 552
Cleland, J., Cohen-Solal, A., Aguilar, J. C., Dietz, R., Eastaugh, J., Follath, F., Freemantle, N., Gavazzi, A., van Gilst, W., Hobbs, F., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11601-1 · Cited by 535
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Extracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis
Memmott, R. M., Mercado, J. R., Maier, C. R., Kawabata, S., Fox, S. D., & Dennis, P. A. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0055 · Cited by 408
Ouwerkerk, W., Voors, A. A., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., van der Harst, P., Hillege, H. L., Lang, C. C., ter Maaten, J. M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx026 · Cited by 404
Regulatory T cells in cardiovascular diseases
Meng, X., Yang, J., Dong, M., Zhang, K., Tu, E., Gao, Q., Chen, W., Zhang, C., & Zhang, Y. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.169 · Cited by 402
Huelsmann, M., Neuhold, S., Resl, M., Strunk, G., Brath, H., Francesconi, C., Adlbrecht, C., Prager, R., Luger, A., Pacher, R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.069 · Cited by 385 · cited 12×
“Although women come to occupy an ever-increasing group of HF patients, European surveys have provided the statistics that men have better odds to receive treatment with ACE inhibitors, b-blockers, and mineralocorticoid receptor antagonists (MRAs) compared with women (odds ratio 1.34, CI 1.22–1.48).58,59 Although diffe…”
ResultInfluentialHeart Failure Stimulates Tumor Growth by Circulating Factors
Meijers, W. C., Maglione, M., Bakker, S. J. L., Oberhuber, R., Kieneker, L. M., de Jong, S., Haubner, B. J., Nagengast, W. B., Lyon, A. R., van der Vegt, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.030816 · Cited by 385
Self-citationHo, J. E., Enserro, D., Brouwers, F. P., Kizer, J. R., Shah, S. J., Psaty, B. M., Bartz, T. M., Santhanakrishnan, R., Lee, D. S., Chan, C., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.003116 · Cited by 362
Self-citationRole of Cholesterol in the Development and Progression of Breast Cancer
Llaverias, G., Danilo, C., Mercier, I., Daumer, K., Capozza, F., Williams, T. M., Sotgia, F., Lisanti, M. P., & Frank, P. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.005 · Cited by 327
Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure
Bansal, S. S., Ismahil, M. A., Goel, M., Patel, B., Hamid, T., Rokosh, G., & Prabhu, S. D. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.116.003688 · Cited by 323
β-Blocker Therapy in Heart Failure: Scientific Review
Foody, J. M., Farrell, M. H., & Krumholz, H. M. (2002) · JAMA · doi:10.1001/jama.287.7.883 · Cited by 322
Cardiac macrophages and their role in ischaemic heart disease
Frantz, S., & Nahrendorf, M. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu025 · Cited by 310
Rapid recruitment of inflammatory monocytes is independent of neutrophil migration
Henderson, R. B., Hobbs, J. A. R., Mathies, M., & Hogg, N. (2003) · Blood · doi:10.1182/blood-2002-10-3228 · Cited by 309
de Boer, R. A., De Keulenaer, G., Bauersachs, J., Brutsaert, D., Cleland, J. G., Diez, J., Du, X.-J., Ford, P., Heinzel, F. R., Lipson, K. E., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1406 · Cited by 304
Self-citationRole of Lymphocytes in Myocardial Injury, Healing, and Remodeling After Myocardial Infarction
Hofmann, U., & Frantz, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.304072 · Cited by 296
Pedersen, S. A., Gaist, D., Schmidt, S. A. J., Hölmich, L. R., Friis, S., & Pottegård, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.11.042 · Cited by 294
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
De Bock, K., Mazzone, M., & Carmeliet, P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.83 · Cited by 293
Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes
Zhang, Z.-J., Zheng, Z.-J., Kan, H., Song, Y., Cui, W., Zhao, G., & Kip, K. E. (2011) · Diabetes Care · doi:10.2337/dc11-0512 · Cited by 291
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 291
Stocks, T., Van Hemelrijck, M., Manjer, J., Bjørge, T., Ulmer, H., Hallmans, G., Lindkvist, B., Selmer, R., Nagel, G., Tretli, S., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.189258 · Cited by 286
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
Effect of Smoking Reduction on Lung Cancer Risk
Godtfredsen, N. S. (2005) · JAMA · doi:10.1001/jama.294.12.1505 · Cited by 275
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Patients With Heart Failure Have an Increased Risk of Incident Cancer
Hasin, T., Gerber, Y., McNallan, S. M., Weston, S. A., Kushwaha, S. S., Nelson, T. J., Cerhan, J. R., & Roger, V. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.088 · Cited by 245
Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer
Hasin, T., Gerber, Y., Weston, S. A., Jiang, R., Killian, J. M., Manemann, S. M., Cerhan, J. R., & Roger, V. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.04.053 · Cited by 227
Dobbins, M., Decorby, K., & Choi, B. C. K. (2013) · ISRN Preventive Medicine · doi:10.5402/2013/680536 · Cited by 227
Vascular Complications of Cancer Chemotherapy
Cameron, A. C., Touyz, R. M., & Lang, N. N. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.12.023 · Cited by 214
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Cancer risk with folic acid supplements: a systematic review and meta-analysis
Wien, T. N., Pike, E., Wisløff, T., Staff, A., Smeland, S., & Klemp, M. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000653 · Cited by 199
Zhang, D., Yong Ma, Q., Hu, H.-T., & Zhang, M. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.1.11944 · Cited by 195
Calcium-channel blockers and risk of cancer
Jick, H., Jick, S., Derby, L. E., Vasilakis, C., Myers, M. W., & Meier, C. R. (1997) · The Lancet · doi:10.1016/s0140-6736(97)80084-0 · Cited by 192
Cancer risk associated with chronic diseases and disease markers: prospective cohort study
Tu, H., Wen, C. P., Tsai, S. P., Chow, W.-H., Wen, C., Ye, Y., Zhao, H., Tsai, M. K., Huang, M., Dinney, C. P., et al. (2018) · BMJ · doi:10.1136/bmj.k134 · Cited by 191
Frantz, S., Falcao-Pires, I., Balligand, J.-L., Bauersachs, J., Brutsaert, D., Ciccarelli, M., Dawson, D., de Windt, L. J., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 184
de Boer, R. A., Pinto, Y. M., & van Veldhuisen, D. J. (2003) · Microcirculation · doi:10.1038/sj.mn.7800188 · Cited by 180
Linking Heart Failure to Cancer: Background Evidence and Research Perspectives
Bertero, E., Canepa, M., Maack, C., & Ameri, P. (2018) · Circulation · doi:10.1161/circulationaha.118.033603 · Cited by 178
A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B
Keramati, A. R., Fathzadeh, M., Go, G., Singh, R., Choi, M., Faramarzi, S., Mane, S., Kasaei, M. M., Sarajzadeh, K., Hwa, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1301824 · Cited by 163
Distress, anxiety, and depression in cancer patients undergoing chemotherapy
Pandey, M., Sarita, G. P., Devi, N., Thomas, B. C., Hussain, B. M., & Krishnan, R. (2006) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-4-68 · Cited by 159
The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors
van der Ende, M. Y., Hartman, M. H. T., Hagemeijer, Y. P., Meems, L. M. G., de Vries, H. S., Stolk, R. P., de Boer, R. A., Sijtsma, A., van der Meer, P., Rienstra, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.061 · Cited by 141
Abraham, D., Hofbauer, R., Schäfer, R., Blumer, R., Paulus, P., Miksovsky, A., Traxler, H., Kocher, A. A., & Aharinejad, S. (2000) · Circulation Research · doi:10.1161/01.res.87.8.644 · Cited by 140
Searching for New Mechanisms of Myocardial Fibrosis with Diagnostic and/or Therapeutic Potential
Heymans, S. R. B., González, A., Pizard, A., Papageorgiou, A., López‐Andrés, N., Jaisser, F., Thum, T., Zannad, F. M., & Díez, J. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.312 · Cited by 139
Predictors and Outcomes of Heart Failure with Mid-Range Ejection Fraction
Bhambhani, V., Kizer, J. R., Lima, J. A. C., van der Harst, P., Bahrami, H., Nayor, M. G., de Filippi, C. R., Enserro, D. M., Blaha, M. J., Cushman, M., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1091 · Cited by 134
Ballotari, P., Vicentini, M., Manicardi, V., Gallo, M., Ranieri, S. C., Greci, M., & Rossi, P. G. (2017) · BMC Cancer · doi:10.1186/s12885-017-3696-4 · Cited by 120
Therapeutic angiogenesis for heart failure
Isner, J. M., & Losordo, D. W. (1999) · Nature Medicine · doi:10.1038/8374 · Cited by 116
Komanduri, S., Jadhao, Y., Guduru, S., Cheriyath, P., & Wert, Y. (2017) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2016.1264696 · Cited by 116
Pollak, M. (2014) · Nature Medicine · doi:10.1038/nm.3596 · Cited by 115
Role of Aspirin in Cancer Prevention
Thorat, M. A., & Cuzick, J. M. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0351-3 · Cited by 115
Christopoulos, P., Pfeifer, D., Bartholomé, K., Follo, M., Timmer, J., Fisch, P., & Veelken, H. (2011) · Blood · doi:10.1182/blood-2010-07-299321 · Cited by 112
Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors In Vivo
Pelton, K., Coticchia, C. M., Curatolo, A. S., Schaffner, C. P., Zurakowski, D., Solomon, K. R., & Moses, M. A. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.03.006 · Cited by 109
Population Risk Prediction Models for Incident Heart Failure: A Systematic Review
Echouffo-Tcheugui, J. B., Greene, S. J., Papadimitriou, L., Zannad, F. M., Yancy, C. W., Gheorghiade, M., & Butler, J. (2015) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001896 · Cited by 107
Obesity and the tumor microenvironment
Olson, O. C., Quail, D. F., & Joyce, J. A. (2017) · Science · doi:10.1126/science.aao5801 · Cited by 104
Clinical prediction of incident heart failure risk: a systematic review and meta-analysis
Yang, H., Negishi, K., Otáhal, P., & Marwick, T. H. (2015) · Open Heart · doi:10.1136/openhrt-2014-000222 · Cited by 103
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Jain, M. K., & Townsend, R. R. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0058-7 · Cited by 92
Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
Rinde, L. B., Småbrekke, B., Hald, E. M., Brodin, E. E., Njølstad, I., Mathiesen, E. B., Løchen, M., Wilsgaard, T., Brækkan, S. K., Vik, A., et al. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0231-5 · Cited by 87
Imaging Systemic Inflammatory Networks in Ischemic Heart Disease
Nahrendorf, M., Frantz, S., Świrski, F. K., Mulder, W. J. M., Randolph, G. J., Ertl, G., Ntziachristos, V., Piek, J. J., Stroes, E. S. G., Schwaiger, M., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.034 · Cited by 83
Tie, G., Yan, J., Khair, L., Messina, J. A., Deng, A., Kang, J., Fazzio, T. G., & Messina, L. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1916 · Cited by 80
Insights into innate immune signalling in controlling cardiac remodelling
Zhang, Y., Huang, Z., & Li, H. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx130 · Cited by 67
Incidence of New‐Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
Fraeman, K. H., Nordstrom, B. L., Luo, W., Landis, S., & Shantakumar, S. (2013) · International Journal of Hypertension · doi:10.1155/2013/379252 · Cited by 61
Jacobs, L., Efremov, L., Ferreira, J. P., Thijs, L., Yang, W., Zhang, Z., Latini, R., Masson, S., Agabiti, N., Sever, P. S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005231 · Cited by 57
Grimaldi‐Bensouda, L., Klungel, O. H., Kurz, X., de Groot, M., Afonso, A. S. M., Bruin, M. L. D., Reynolds, R. F., & Rossignol, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009147 · Cited by 51
Brouwers, F. P. J., Hillege, H. L., van Gilst, W. H., & van Veldhuisen, D. J. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0115-7 · Cited by 40
Mirk/dyrk1B Kinase in Ovarian Cancer
Friedman, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035560 · Cited by 39
Liu, J., Dai, X., Xu, Y., Liu, P., Zhang, Y., Liu, X., Fang, Z., Lin, D.-J., Xiao, R., Huang, R., et al. (2011) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-011-9253-x · Cited by 38
Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study
Weberpals, J. G., Jansen, L., Haefeli, W. E., Hoffmeister, M., Wolkewitz, M., van Herk‐Sukel, M. P. P., Vissers, P. A. J., & Brenner, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-02913-8 · Cited by 37
Akinyemiju, T., Wiener, H. W., & Pisu, M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3557-1 · Cited by 37
Is obesity an advantage in patients with colorectal cancer?
Kasi, P. M., Zafar, S. Y., & Grothey, A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1089170 · Cited by 34
Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis
Kim, H. Y., Jung, Y. J., Lee, S. H., Jung, H. J., & Pak, K. (2017) · Oncology · doi:10.1159/000455143 · Cited by 34
Ebert, B. L., & Libby, P. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0737 · Cited by 34
Suthahar, N., Meijers, W. C., Brouwers, F. P. J., Heerspink, H. J. L., Gansevoort, R. T., van der Harst, P., Bakker, S. J. L., & de Boer, R. A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.035 · Cited by 33
Self-citationCompeting Risks of Cancer Mortality and Cardiovascular Events in Individuals with Multimorbidity
Bayliss, E. A., Reifler, L. M., Zeng, C. X., McQuillan, D. B., Ellis, J. L., & Steiner, J. F. (2014) · Journal of Comorbidity · doi:10.15256/joc.2014.4.41 · Cited by 32
Management of Heart Failure in Cancer Patients and Cancer Survivors
Finet, J. E. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.12.004 · Cited by 28
Lotan, K., Goldbourt, U., & Gerber, Y. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.052 · Cited by 15
Ghosh, R., Ray, U., Jana, P., Bhattacharya, R., Banerjee, D., & Sinha, A. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088639 · Cited by 12
Imran, S. (2017) · Nursing & Care Open Access Journal · doi:10.15406/ncoaj.2017.02.00053 · Cited by 6
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
Cardiovascular disease and cancer: shared risk factors and mechanisms
Wilcox, N. S., Amit, U., Reibel, J. B., Berlin, E., Howell, K., & Ky, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01017-x · Cited by 310
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51
Self-citation
Metadata
- Authors
- Meijers, W. C., & de Boer, R. A.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-04
- Volume
- 115
- Issue
- 5
- Pages
- 844-853
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W2914181080
- Cited by
- 314
- References
- 122
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.